‘Own your health’ with Hylid Diagnostics
Hylid Diagnostics (HyliDx) will improve the lives of millions of people with kidney disease and heart failure, saving healthcare systems thousands of dollars per patient each year
The problem: A vicious and costly cycle of chronic disease
The total US Healthcare cost of the three related diseases in the image—comprising CardioRenal Metabolic Syndrome—is $388 billion
Diabetes costs and outcomes have improved with internet-connected home blood tests and remote care
However, chronic kidney disease (CKD) and heart failure (HF) still suffer from:
- High and growing costs (> diabetes), largely due to unnecessary hospitalization
- Poor outcomes—low quality of life and productivity, high mortality
- No effective home testing or remote care capability
The solution: HyliDx home testing and remote care platform
- Simple, lab-accurate blood tests for chronic disease monitoring
- Test results within 5 min from a small, finger-prick sample of blood
- Results immediately uploaded, via our HyliDx eHealth patient app, to electronic medical records and remote caregivers
- Patients and caregivers can communicate, by messaging or virtual visit, to enhance patient engagement in therapy
- HyliDx Cloud AI flags abnormal data or trends, and eventually predicts and helps avoid complications/hospitalizations
Chronic Kidney Disease (CKD) and Heart Failure (HF) in numbers:
Sufferers in US, Canada, and Europe
Total treatment cost
The use: Main applications of the HyliDx system
Patients with advanced CKD
- To delay onset of costly kidney failure, particularly in remote areas
- 20-25M in North America and Europe
Patients on dialysis
- More than 1M on dialysis in NA, EU
- Dialysis patients need routine monitoring, which is especially difficult with home dialysis
Doctors' offices
- To save existing CKD and HF patients extra travel to a blood lab prior to their appointments, and to improve early-CKD diagnosis rates (allowing more time for treatment)
High-risk CKD/HF patients at any stage
- For medication dosing/monitoring, and for vulnerable patients on release from hospital to avoid costly readmission
The opportunity
$50B in cost savings
In the US and Canada alone, HyliDx can save healthcare more than $50B in treatment costs
Outstanding team and tech
We have a highly-qualified and experienced senior team (see below), several clinical and business advisors, and a working prototype
Improved patient outcomes
With the HyliDx system at home, patients can keep themselves healthier and slow disease progression
HyliDx Executive Team
(click images for bios)
Jack Fairbank, CEO
Past: Senior Key Expert, Siemens Healthineers
Navin Dewagan, CIO
Past: Director of Digital Health and Software, Fresenius Medical
Sepehr Molazemhosseini, Director of Sensor Design
Past: CTO, Sensoreal Inc.
Sape de Vries, Director of Cartridge Design
Past: Director of Engineering, Siemens Healthineers
Marco Witteveen, Director of Strategy & BD
Past: International Director of Sales & Marketing, Alere
Jack has designed sensors, diagnostic instruments, cartridges, software, and manufacturing systems for 13 years. Recognized as a Senior Key Expert at Siemens, Jack developed a host of critical control systems for next-generation Siemens hospital blood analyzers (handheld and benchtop). Previously, he contributed substantially to the development of various Alere/Abbott diagnostic systems: SoToxa, eScreen eREADER+, and DIGIVAL. One of his designs received an innovation award from Popular Scientist. Jack has a PhD from Dalhousie, Postdocs from Harvard and McGill, BEng major and BComm minor from McMaster, Master’s in Business Strategy from Oxford, and a Certificate in Finance from Harvard.
Navin has 20 years of experience in all technical aspects of Digital Health: electronics and software design, validation, regulatory expertise, IoT/cloud, cybersecurity, and mobile software development. His other company, Digital Health Solutions, developed—in partnership with Microsoft—the mobile communications platform and app that HyliDx will use. Previously, as Director of Software Development at Fresenius Medical Care, the world’s largest provider of dialysis products and services, Navin gained industry knowledge of particular value to HyliDx.
Sepehr brings 10 years of hands-on R&D experience in biosensing technology, specializing in electrical and electrochemical biosensors, microfabrication, signal transduction, and immunoassay design. His innovative work appears in 23 publications (with 600+ citations) in top journals, and a US patent on electrochemical biosensors for point-of-care applications. During his post-doctoral work, Sepehr led technology transfer projects with major pharmaceutical companies like Bracco S.p.A. As CTO at Sensoreal Inc., a Montreal-based startup, he directed the development of the company’s first product PSPAlert and helped secure over $1 million in non-dilutive funding. Sepehr holds a PhD in Materials Science and Engineering from Polytechnic Milan.
Sape has 15 years of experience designing medical device consumables and highly-automated manufacturing equipment for those consumables—which currently make tens of millions of units per year. As Director of R&D Engineering at the Epocal Division of Siemens, he was responsible for test-cartridge design for Siemens ‘epoc’ blood analyzers and contributed to many stages of the development process, from R&D to New Product Introduction. Sape has a Master’s of Mechanical Engineering from Queen’s University.
Marco has held senior sales, marketing, and product positioning roles in three leading near-patient testing companies, over 20 years. At Abbott he was Netherlands National Sales Director. At Alere (now Abbott), he launched the Siemens ‘epoc’ blood analyzer globally (outside the US) and was International Marketing Director. Then at Instrumentation Laboratory, a major manufacturer of hospital blood analyzers, he was a Director and built the product strategy for all main hospital units (ED, ICU, NICU, and hospital laboratories), with responsibility for P&L and customer support.
Advisors
Seppo Makinen, Business Advisor
12 Exits and over 40 Board Memberships in international Diagnostics and Life Sciences companies
Dr Erika Bariciak, Clinical Advisor
Assistant Professor in the Faculty of Medicine at the University of Ottawa, and Adjunct Professor in the Department of Systems and Computer Engineering at Carleton University
Robert Fraatz, Technical Advisor
Helped lead the development of the OPTI blood analyzer—instrument and sensors—from concept to launch, then acquisition by Roche
Dr Alp Sener, Clinical Advisor (Canada)
Chair and city-wide Chief of Urology and Director of the Kidney/Pancreas Transplant Fellowship Program at the University of Western Ontario
Dr Saif Muhsin, Clinical Advisor (US)
Transplant Nephrologist and Co-Director of Kidney Disease Clinic, Brigham and Women’s Hospital, Harvard University, USA
Dr Amir Bhanji, Clinical Advisor (UK)
Care Group Director for Renal and Transplantation, and Lead for Hemodialysis Program, Portsmouth Hospitals NHS Trust, UK
HyliDx also has contract Regulatory Advisors who are experts in FDA, EU, Health Canada, and UK medical device regulations, as well as ISO 13485 and QMS requirements (for which they are expert auditors)
Karim Galzahr, Board Member
Principal, OKG Capital. 30 years of experience in finance including M&A, asset management, corporate development, and strategic advisory work across the technology sector in general and the medical technology area in particular.
Partners
Contact HyliDx
Hylid Diagnostics Inc. (HyliDx)
5310 Canotek Road, Unit 28F, Ottawa, Ontario K1J 9N5, CANADA
Phone: +1 613 686 3900
Email: [email protected]